Advertisement
Radiopharm Theranostics L... (RADX)
Radiopharm Theranostics Statistics
Share Statistics
Radiopharm Theranostics has - shares outstanding. The number of shares has increased by null% in one year.
Shares Outstanding | - |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Institutions (%) | n/a |
Shares Floating | - |
Failed to Deliver (FTD) Shares | 3K |
FTD / Avg. Volume | 1.59% |
Short Selling Information
Short Interest | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is null and the forward PE ratio is null.
PE Ratio | null |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Radiopharm Theranostics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of null, with a Debt / Equity ratio of null.
Current Ratio | null |
Quick Ratio | null |
Debt / Equity | null |
Debt / EBITDA | - |
Debt / FCF | - |
Interest Coverage | null |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $- |
Profits Per Employee | $- |
Employee Count | undefined |
Asset Turnover | null |
Inventory Turnover | n/a |
Taxes
Income Tax | - |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 0.87, so Radiopharm Theranostics's price volatility has been higher than the market average.
Beta | 0.87 |
52-Week Price Change | null% |
50-Day Moving Average | 5.05 |
200-Day Moving Average | null |
Relative Strength Index (RSI) | 37.66 |
Average Volume (20 Days) | 188.29K |
Income Statement
Revenue | n/a |
Gross Profit | - |
Operating Income | - |
Net Income | - |
EBITDA | - |
EBIT | n/a |
Earnings Per Share (EPS) | null |
Balance Sheet
The company has - in cash and - in debt, giving a net cash position of 0.
Cash & Cash Equivalents | - |
Total Debt | - |
Net Cash | 0 |
Retained Earnings | - |
Total Assets | - |
Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was - and capital expenditures -, giving a free cash flow of -.
Operating Cash Flow | - |
Capital Expenditures | - |
Free Cash Flow | - |
FCF Per Share | null |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
RADX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for RADX is $15, which is 284.6% higher than the current price. The consensus rating is "Buy".
Price Target | $15 |
Price Target Difference | 284.6% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Scores
Altman Z-Score | null |
Piotroski F-Score | null |